Amir Hefni is Vice President and Global Commercial Head for Cell & Gene, having joined Novartis in May 2020.
He is accountable for developing and implementing Go To Market commercial strategy for all CAR-T products across indications and disease areas.
Amir joined Novartis from Ipsen, where he was an oncology brand Global General Manager and was critical in launching multiple indications, driving significant global brand growth and driving a rich Life Cycle Management program.
Previously, he was with Bristol-Myers Squibb (BMS) for 11 years, roles included Executive Director, US Oncology Thoracic Lead, where he led NSCLC, SCLC, and SCCHN. Furthermore, Amir brings a wealth of experience working across different markets including US, UK/Ireland and Sweden. He held various positions of increasing responsibility in the BMS commercial organization: from Business Unit Head in the UK/Ireland to roles within the Worldwide Commercial group, General Manager in Sweden and International Markets Strategy & Operations.
Amir holds a BSc and PhD in Pharmacology from King’s College London, University of London (UK) and an MBA from Warwick Business School, University of Warwick (UK). He also completed the General Management Program (GMP) at CEDEP/INSEAD in 2017.